Akero Therapeutics (AKRO) Jumps 16% on $5.2-Billion Novo Nordisk Merger

We recently published 10 Big Names With Whopping Gains; 6 Jump All-Time Highs. Akero Therapeutics, Inc. (NASDAQ:AKRO) is one of the best performers on Thursday.

Akero Therapeutics saw its share prices jump by 16.33 percent on Thursday to end at $54.08 apiece following announcements that it was set to merge with Novo Nordisk in a $5.2 billion deal.

In a statement, Akero Therapeutics, Inc. (NASDAQ:AKRO) said both companies officially entered into a definitive agreement, under which Novo Nordisk would acquire all AKRO shares at a price of $54 apiece alongside a non-transferable contingent value right (CVR) upon the achievement of a milestone.

Each shareholder will be entitled to receive cash worth $6 upon full US regulatory approval of efruxifermin, a potential treatment for compensated cirrhosis due to MASH, by June 30, 2031.

Akero Therapeutics, Inc. (NASDAQ:AKRO) said the offer price represents a 19 percent premium over its 30-day volume-weighted average price (VWAP), and a 42 percent premium to its closing price on May 19, prior to market speculation.

Akero Therapeutics, Inc.’s (NASDAQ:AKRO) EFX program, focused on developing treatment for MASH, would complement Novo’s leadership in GLP-1-based metabolic treatments.

While we acknowledge the potential of AKRO as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.